Shares of Laurus Labs were trading at Rs 476 at 10:49 IST on BSE, a premium of 11.27% over the initial public offer price of Rs 428.
The stock debuted at Rs 490, a premium of 14.49% to the initial public offer (IPO) price. So far the stock hit a high of Rs 498 and low of Rs 475. On BSE, so far 22.20 lakh shares were traded on the counter.
The initial public offer (IPO) of Laurus Labs opened on 6 December and closed on 8 December 2016. The issue received bids for 10.01 crore shares compared with 2.19 crore shares on offer. The IPO was subscribed 4.57 times.
The IPO comprised of fresh issue of Rs 300 crore and the offer for sale of 2.41 crore shares by the selling shareholders. The qualified institutional buyers (QIBs) category was subscribed 10.54 times. The non-institutional investors' category was subscribed 3.58 times. The retail investors category was subscribed 1.67 times.
The company proposes to utilise the net proceeds from the fresh issue towards the pre-payment of term loans and the general corporate purposes. In addition the company expects to receive the benefits of listing of the shares on the stock exchanges, enhancement of the company's brand name and creation of a public market for shares.
For the six months ended 30 September 2016, Laurus Labs reported consolidated net profit of Rs 75.10 crore on total revenue of Rs 941.78 crore.
Laurus Labs is a leading research and development (R&D) driven pharmaceutical company, with a leadership position in generic active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. The company also manufactures APIs in oncology and other therapeutic areas. The company operates in four business lines: generics-APIs, generics-FDFs, synthesis and ingredients.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
